Prevalence of Circulating Parvovirus Genome in Recently Diagnosed Graves' Disease: a Case-control Study

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT02798965

Acronym

GPCBasedow

Enrollment

Registered

2016-06-14

Start date

2010-12-31

Completion date

2014-05-31

Last updated

2025-11-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Graves Disease

Keywords

parvovirus genome

Brief summary

Lymphocytic thyroiditis is the most common autoimmune disease, usually affecting young women. Although the aetiology and pathogenesis remain obscure, the most widely accepted hypothesis is an interaction between a genetic predisposition and an environmental trigger factor such as viral infection. Parvovirus infections have been proposed as trigger factors for Hashimoto's thyroiditis and Graves' disease.

Interventions

BIOLOGICALserodiagnosis

Study design

Allocation

NON_RANDOMIZED

Intervention model

PARALLEL

Primary purpose

BASIC_SCIENCE

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to 99 Years

Healthy volunteers

Inclusion criteria

* Graves' disease :patients treated for Graves' disease, the diagnosis date less than 4 months * Control : patients cared for nodules or goiter

Exclusion criteria

* Patients undergoing immunosuppressive therapy including corticosteroids

Design outcomes

Primary

Measure	Time frame
prevalence of circulating parvovirus genome	Day 0

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026